Thomas Dick, Ph.D., is a Member of the Center for Discovery and Innovation.
Dr. Dick has 20 years of experience in antibacterial drug discovery and R&D program management. Prior to his current appointment as Member at CDI, he was Tuberculosis (TB) disease area head at Novartis and served as a professor at the National University of Singapore and at Rutgers, Newark. Dr. Dick studied at the University of Heidelberg where he obtained his Ph.D. in molecular bacteriology. He published over 100 papers in the area of antibiotic resistance and discovery with an h-index of 43.
Dr. Dick’s research focuses on the discovery of new medicines for the treatment of TB and lung disease caused by Non-Tuberculous Mycobacteria (NTM). At CDI in collaboration with Drs Dartois and Gengenbacher, he established a fully enabled drug discovery platform for the delivery of preclinical development candidates. Along with partners from industry and academia, Dr. Dick developed an attractive portfolio of repositioning and de novo drug discovery projects. Recently, he secured grant support for NTM drug discovery of over $5M from NIH and the Cystic Fibrosis Foundation. After showing that the TB drug pyrazinamide is a target degrader, he obtained $2.5M from NIH for the development of next-generation pyrazinamide.